Serum IgG levels after rituximab therapy for pediatric patients with NHL demonstrate heterogeneity in time to recovery, with hypogammaglobulinemia defined as <500 mg/dL. Twenty percent (4/20) remained hypogammaglobulinemic >24 months after ending therapy, with a paucity of switched memory B cells. All 4 patients have required IVIG therapy for persistent infections.